David MartÃ-nez-CuadrÃ³n

List of Publications by Year
in descending order

47 papers	652 citations	623574 14 h-index	642610 23 g-index
47 all docs	47 docs citations	47 times ranked	945 citing authors

#	Article	IF	Citations
1	Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. Blood Advances, 2022, 6, 1278-1295.	2.5	29
2	Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. Leukemia, 2022, 36, 913-922.	3.3	23
3	Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia. Expert Opinion on Emerging Drugs, 2022, 27, 1-18.	1.0	7
4	Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience. Cancers, 2022, 14, 1734.	1.7	13
5	Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry. Leukemia Research, 2022, 115, 106821.	0.4	3
6	Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia. Pharmaceutics, 2022, 14, 878.	2.0	5
7	Healthcare Resource Utilization among Patients between 60â€“75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study. Cancers, 2022, 14, 1921.	1.7	1
8	Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry. Cancers, 2022, 14, 2342.	1.7	4
9	Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia. Cancers, 2022, 14, 2817.	1.7	0
10	A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries. Blood Cancer Journal, 2022, 12, .	2.8	4
11	Evolving treatment patterns and outcomes in older patients (â‰¥60 years) with AML: changing everything to change nothing?. Leukemia, 2021, 35, 1571-1585.	3.3	12
12	Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 659-668.	0.6	10
13	Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation. Future Oncology, 2021, 17, 215-227.	1.1	0
14	Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial. Blood Advances, 2021, 5, 760-770.	2.5	18
15	Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia. Leukemia, 2021, 35, 2358-2370.	3.3	31
16	A phase 3 trial of azacitidine versus a semiâ€intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia. Cancer, 2021, 127, 2003-2014.	2.0	16
17	Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain. European Journal of Haematology, 2021, 106, 724-733.	1.1	1
18	A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients. Annals of Hematology, 2021, 100, 1497-1508.	0.8	7

#	Article	IF	Citations
19	Extracorporeal photopheresis vs standard therapies for steroidâ€refractory chronic graftâ€vsâ€host disease: Pharmacoeconomic assessment of hospital resource use in Spain. Journal of Clinical Apheresis, 2021, 36, 612-620.	0.7	2
20	The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial. Cancers, 2021, 13, 2458.	1.7	7
21	Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients. Leukemia and Lymphoma, 2021, 62, 2727-2736.	0.6	0
22	Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project. Haematologica, 2021, 106, 3079-3089.	1.7	15
23	Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis. Cancers, 2021, 13, 5677.	1.7	8
24	Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports. Clinical Drug Investigation, 2020, 40, 227-235.	1.1	2
25	Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia. Annals of Hematology, 2020, 99, 1989-2007.	0.8	26
26	Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?. Expert Review of Hematology, 2020, 13, 1057-1065.	1.0	5
27	Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity. British Journal of Haematology, 2020, 189, 672-683.	1.2	11
28	Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?. Blood Reviews, 2020, 44, 100675.	2.8	23
29	Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study. Leukemia Research, 2020, 92, 106352.	0.4	0
30	PLZF-RARÎ±, NPM1-RARÎ±, and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review. Cancers, 2020, 12, 1313.	1.7	20
31	Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry. Blood, 2020, 136, 25-27.	0.6	3
32	Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review. Expert Review of Clinical Pharmacology, 2019, 12, 197-218.	1.3	15
33	Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis. Annals of Hematology, 2019, 98, 2081-2088.	0.8	16
34	Real life outcomes of patients aged â‰¥75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry. Leukemia and Lymphoma, 2019, 60, 2720-2732.	0.6	2
35	DIFFERENCES IN EX-VIVO CHEMOSENSITIVITY TO ANTHRACYCLINES IN FIRST LINE ACUTE MYELOID LEUKEMIA. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019016.	0.5	3
36	Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics. Journal of Molecular Diagnostics, 2019, 21, 228-240.	1.2	24

#	Article	IF	Citations
37	Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain. PharmacoEconomics - Open, 2019, 3, 229-235.	0.9	3
38	A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients. Leukemia Research, 2019, 76, 1-10.	0.4	15
39	A Predictive Model for Early Death after Frontline Hypomethylating Agents in Elderly Unfit Acute Myeloid Leukemia Patients: Results from the Pethema Group. Blood, 2019, 134, 648-648.	0.6	1
40	Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review. Annals of Hematology, 2018, 97, 1115-1153.	0.8	81
41	Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia. Current Drug Metabolism, 2018, 19, 55-74.	0.7	22
42	Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin. Annals of Hematology, 2017, 96, 1077-1084.	0.8	8
43	Impact ofABCsingle nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. Leukemia and Lymphoma, 2017, 58, 1197-1206.	0.6	33
44	A prognostic model for survival after salvage treatment with <scp>FLAG</scp>â€da +/â^' gemtuzumabâ€ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia. British Journal of Haematology, 2016, 174, 700-710.	1.2	44
45	Pharmacogenomics and the treatment of acute myeloid leukemia. Pharmacogenomics, 2016, 17, 1245-1272.	0.6	25
46	Pharmacological Profiles of Acute Myeloid Leukemia Treatments in Patient Samples by Automated Flow Cytometry: A Bridge to Individualized Medicine. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 305-318.	0.2	30
47	A scoring system to predict the risk of death during induction with anthracycline plus cytarabineâ€based chemotherapy in patients with de novo acute myeloid leukemia. Cancer, 2012, 118, 410-417.	2.0	24